NASDAQ:DRAD - Digirad Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.00 -0.05 (-4.78 %) (As of 03/26/2019 01:13 PM ET)Previous Close$1.05Today's Range$0.99 - $1.0752-Week Range$0.42 - $2.00Volume62,481 shsAverage Volume176,549 shsMarket Capitalization$20.15 millionP/E RatioN/ADividend Yield10.68%Beta2.48 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Digirad Corporation provides healthcare solutions in the United States. It operates through Diagnostic Services, Mobile Healthcare, and Diagnostic Imaging segments. The Diagnostic Services segment provides nuclear and ultrasound imaging services to physicians who perform nuclear imaging, echocardiography, vascular or general ultrasound tests, imaging systems, radiopharmaceuticals, and licensing services, as well as offers remote cardiac event monitoring services. The Mobile Healthcare segment offers contract diagnostic imaging services, including computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), PET/CT, and nuclear medicine and healthcare services to hospitals, integrated delivery networks, and federal institutions on a long-term contract basis, as well as provisional services to institutions that are in transition. The Diagnostic Imaging segment develops and sells gamma camera imaging systems, such as nuclear cardiac imaging systems and general purpose nuclear imaging systems to physician offices and hospitals; and offers camera maintenance services. Digirad Corporation was founded in 1985 and is headquartered in Suwanee, Georgia. Receive DRAD News and Ratings via Email Sign-up to receive the latest news and ratings for DRAD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRAD Previous Symbol CUSIPN/A CIK707388 Webwww.digirad.com Phone858-726-1600Debt Debt-to-Equity Ratio0.37 Current Ratio1.60 Quick Ratio1.19Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$104.18 million Price / Sales0.19 Cash Flow$0.3102 per share Price / Cash Flow3.21 Book Value$1.28 per share Price / Book0.78Profitability EPS (Most Recent Fiscal Year)N/A Net Income$740,000.00 Net Margins0.71% Return on Equity-9.83% Return on Assets-5.00%Miscellaneous Employees452 Outstanding Shares20,230,000Market Cap$20.15 million Next Earnings Date5/7/2019 (Estimated) OptionableOptionable Digirad (NASDAQ:DRAD) Frequently Asked Questions What is Digirad's stock symbol? Digirad trades on the NASDAQ under the ticker symbol "DRAD." How often does Digirad pay dividends? What is the dividend yield for Digirad? Digirad declared a quarterly dividend on Friday, August 3rd. Investors of record on Thursday, August 16th will be given a dividend of $0.055 per share on Thursday, August 30th. This represents a $0.22 annualized dividend and a yield of 22.09%. The ex-dividend date of this dividend is Wednesday, August 15th. View Digirad's Dividend History. How were Digirad's earnings last quarter? Digirad Co. (NASDAQ:DRAD) released its quarterly earnings data on Thursday, August, 2nd. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.02) by $0.04. The medical equipment provider earned $27.08 million during the quarter. Digirad had a net margin of 0.71% and a negative return on equity of 9.83%. View Digirad's Earnings History. When is Digirad's next earnings date? Digirad is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Digirad. Has Digirad been receiving favorable news coverage? News headlines about DRAD stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Digirad earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. Who are some of Digirad's key competitors? Some companies that are related to Digirad include Edap Tms (EDAP), IRIDEX (IRIX), Soleno Therapeutics (SLNO), Viveve Medical (VIVE), ENDRA Life Sciences (NDRA), Precision Optics (PEYE), Nexeon Medsystems (NXNN), Non-Invasive Monitoring Systems (NIMU), Vaso (VASO), Reshape Lifesciences (RSLS), Aradigm (ARDM), CHF Solutions (CHFS), Escalon Medical (ESMC), Trimedyne (TMED) and Fc Global Realty (FCRE). What other stocks do shareholders of Digirad own? Based on aggregate information from My MarketBeat watchlists, some companies that other Digirad investors own include US Stem Cell (USRM), LightPath Technologies (LPTH), Exelixis (EXEL), Novavax (NVAX), Prospect Capital (PSEC), Rigel Pharmaceuticals (RIGL), Navios Maritime Midstream Partners (NAP), AcelRx Pharmaceuticals (ACRX), Nymox Pharmaceutical (NYMX) and Reshape Lifesciences (RSLS). Who are Digirad's key executives? Digirad's management team includes the folowing people: Mr. Matthew Gabel Molchan, Pres, CEO & Director (Age 52)Mr. Martin B. Shirley, Pres of Digirad Imaging Solutions (Age 57)Mr. Michael Debeauvernet, Exec. Officer (Age 57)Mr. David James Noble, COO & Interim CFO (Age 48)Mr. Bob Halbert, Sr. Director of Human Resource Who are Digirad's major shareholders? Digirad's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Price Wealth Management Inc. (0.30%) and Shepherd Kaplan Krochuk LLC (0.25%). Company insiders that own Digirad stock include Cannell Capital Llc, David James Noble, Jeffrey E Eberwein, Jeffry R Keyes, Matthew G Molchan, Michael A Cunnion and Virgil Lott. View Institutional Ownership Trends for Digirad. Which institutional investors are selling Digirad stock? DRAD stock was sold by a variety of institutional investors in the last quarter, including Shepherd Kaplan Krochuk LLC. View Insider Buying and Selling for Digirad. Which institutional investors are buying Digirad stock? DRAD stock was purchased by a variety of institutional investors in the last quarter, including Price Wealth Management Inc.. Company insiders that have bought Digirad stock in the last two years include Cannell Capital Llc, David James Noble, Jeffrey E Eberwein, Jeffry R Keyes and Matthew G Molchan. View Insider Buying and Selling for Digirad. How do I buy shares of Digirad? Shares of DRAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Digirad's stock price today? One share of DRAD stock can currently be purchased for approximately $0.9959. How big of a company is Digirad? Digirad has a market capitalization of $20.15 million and generates $104.18 million in revenue each year. Digirad employs 452 workers across the globe. What is Digirad's official website? The official website for Digirad is http://www.digirad.com. How can I contact Digirad? Digirad's mailing address is 1048 INDUSTRIAL COURT, SUWANEE GA, 30024. The medical equipment provider can be reached via phone at 858-726-1600 or via email at [email protected] MarketBeat Community Rating for Digirad (NASDAQ DRAD)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 260 (Vote Outperform)Underperform Votes: 201 (Vote Underperform)Total Votes: 461MarketBeat's community ratings are surveys of what our community members think about Digirad and other stocks. Vote "Outperform" if you believe DRAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRAD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: Why is the price-sales ratio important?